Srivastava, A.; Unterweger, C.; Guttmann, S.; Wolf, A.; Müllauer, L.; Schepelmann, M.; Cacsire Castillo-Tong, D.; Bartl, T.
Therapeutic Effects of Lurbinectedin in PARP Inhibitor-Resistant High-Grade Serous Ovarian Cancer Using Patient-Derived Cell Lines and Organoid Models. Int. J. Mol. Sci. 2025, 26, 8866.
https://doi.org/10.3390/ijms26188866
AMA Style
Srivastava A, Unterweger C, Guttmann S, Wolf A, Müllauer L, Schepelmann M, Cacsire Castillo-Tong D, Bartl T.
Therapeutic Effects of Lurbinectedin in PARP Inhibitor-Resistant High-Grade Serous Ovarian Cancer Using Patient-Derived Cell Lines and Organoid Models. International Journal of Molecular Sciences. 2025; 26(18):8866.
https://doi.org/10.3390/ijms26188866
Chicago/Turabian Style
Srivastava, Akshi, Christine Unterweger, Sarah Guttmann, Andrea Wolf, Leonhard Müllauer, Martin Schepelmann, Dan Cacsire Castillo-Tong, and Thomas Bartl.
2025. "Therapeutic Effects of Lurbinectedin in PARP Inhibitor-Resistant High-Grade Serous Ovarian Cancer Using Patient-Derived Cell Lines and Organoid Models" International Journal of Molecular Sciences 26, no. 18: 8866.
https://doi.org/10.3390/ijms26188866
APA Style
Srivastava, A., Unterweger, C., Guttmann, S., Wolf, A., Müllauer, L., Schepelmann, M., Cacsire Castillo-Tong, D., & Bartl, T.
(2025). Therapeutic Effects of Lurbinectedin in PARP Inhibitor-Resistant High-Grade Serous Ovarian Cancer Using Patient-Derived Cell Lines and Organoid Models. International Journal of Molecular Sciences, 26(18), 8866.
https://doi.org/10.3390/ijms26188866